Satisfactory short‐term outcome after anlotinib and docetaxel chemotherapy in tongue cancer with N3 cervical lymph node metastasis: A case report

Patients with tongue squamous cell carcinoma (TSCC) and cervical lymph node metastasis are particularly difficult to treat. This is the first report of about anlotinib combined with docetaxel chemotherapy for chemotherapy‐refractory TSCC with cervical lymph node metastasis, may provide a new, suitable therapeutic option for these patients.

[1]  Arlene E. Chung,et al.  Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) , 2019, J. Am. Medical Informatics Assoc..

[2]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[3]  Yahiya Y. Syed.  Anlotinib: First Global Approval , 2018, Drugs.

[4]  R. Sun,et al.  Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis , 2018, Acta Pharmacologica Sinica.

[5]  N. Lu,et al.  Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. , 2018, Gene.

[6]  I. Tohnai,et al.  Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases. , 2018, Oral oncology.

[7]  T. Salo,et al.  The interplay of matrix metalloproteinase-8, transforming growth factor-β1 and vascular endothelial growth factor-C cooperatively contributes to the aggressiveness of oral tongue squamous cell carcinoma , 2017, British Journal of Cancer.

[8]  I. Tohnai,et al.  Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for T2-4N0 tongue cancer: control of occult neck metastasis. , 2017, Oral surgery, oral medicine, oral pathology and oral radiology.

[9]  W. Figg,et al.  Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model , 2016, Scientific Reports.

[10]  Jay K. Harness,et al.  Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) , 2016, Health and Quality of Life Outcomes.

[11]  A. Argiris,et al.  Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck , 2015, Head & neck.

[12]  Á. Benedict,et al.  Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States. , 2015, Journal of managed care & specialty pharmacy.

[13]  T. Komori,et al.  Vascular endothelial growth factor C (VEGF-C) expression predicts metastasis in tongue cancer. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[14]  G. Hoffman,et al.  Elective neck dissection for primary oral cavity squamous cell carcinoma involving the tongue should include sublevel IIb. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[15]  Wenping Ding,et al.  Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials , 2014, OncoTargets and therapy.

[16]  I. Tohnai,et al.  Thermochemoradiotherapy using superselective intra-arterial infusionfor N3 cervical lymph node metastases of tongue cancer , 2013 .

[17]  J. Shah,et al.  Long‐term regional control and survival in patients with “low‐risk,” early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation , 2013, Cancer.

[18]  Nishiguchi Hiroaki,et al.  Thermochemoradiotherapy using superselective intra-arterial infusion for N3 cervical lymph node metastases of tongue cancer. , 2013, Journal of cancer research and therapeutics.

[19]  M. Ikeda,et al.  Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer , 2012, Acta oto-laryngologica.

[20]  R. Greil,et al.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Lee,et al.  Long Term Regional Control and Survival in Patients with “Low Risk” Early Stage Oral Tongue Cancer Managed by Partial Glossectomy and Neck Dissection without Postoperative Radiation: The Importance of Depth of Invasion , 2011 .

[22]  G. Weinstein,et al.  Multivariate Predictors of Occult Neck Metastasis in Early Oral Tongue Cancer , 2003, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.